

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

B.M. Mehling¹, L. Quartararo¹, M. Manvelyan¹, P. Wang¹, D.-C. Wu^{2,3}

¹Blue Horizon International, LLC, Hackensack, NJ, USA;

²Biochemistry Institute, Wuhan University, Hubei, P.R. China;

³Department of Stem Cells, Wuhan Hongqiao Brain Hospital, Wuhan, Hubei, P.R. China

Corresponding Author: Marine Manvelyan, Ph.D; e-mail: mmanvelyan@bluehorizonhospital.com

Background: Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) in general represent a valuable tool for therapy of symptoms related to chronic inflammatory diseases. Blue Horizon Stem Cell Therapy Program is a leading provider of adult and children's stem cell therapies. Uniquely we have safely and efficiently treated more 600 patients with documenting each procedure.

Materials and methods: The purpose of our study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs), and secondly, to evaluate effects on biomarkers associated with chronic inflammation. Nine patients were treated for conditions associated with chronic inflammation and for the purpose of anti-aging. They have been given one intravenous infusion of UC-MSCs.

Results: Our study of blood test markers of 9 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there is no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation and aging included in initial, 24-hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover data from follow up protocols demonstrates significant improvement in energy level, hair, nails growth and skin conditions.

Conclusions: Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation. Further close monitoring and inclusion of more patients are necessary to fully characterize the

advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.

Keywords: Chronic inflammatory diseases, Umbilical cord blood derived mesenchymal stem cells (UC-MSCs), Intravenous infusion.

INTRODUCTION

Chronic inflammation is characterized by continued active inflammation response and tissue destruction. Immune cells including macrophages, neutrophils and eosinophils are involved in pathology of chronic inflammation directly or by production of inflammatory cytokine production¹. To maintain homeostasis regulated inflammatory responses are essential. Inflammatory responses that fail to regulate themselves can become chronic and contribute to the perpetuation and progression of disease². Over the past decade non-communicable chronic diseases that are potentiated by sterile inflammation have replaced infectious diseases as the major threat to global human health. Improved understanding of the sterile inflammatory process is one of the most important areas of biomedical investigation³. The pharmaceutical industry is searching for better-tolerated anti-inflammatory drugs. Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy in chronic inflammatory diseases. MSCs, multipotent adult stem cells, feature the potential to regenerate tissue damage and inhibit inflammation. MSC can be safely transplanted in autologous and allogeneic ways as they are non-immunogenic, representing a therapeutic option for chronic inflammatory diseases. There are more than 200 registered clinical trial sites for evaluating MSC therapy, and 22 are on autoimmune diseases⁴.

Stem cell therapy is a potential method for treatment of some disorders⁵. Sources for stem cells vary, each of which have uses for certain diseases⁶⁻⁸. MSCs are one source for stem cells that are multipotent, non-hematopoietic and have the capability for self-renewal and differentiation. MSCs can be isolated from different human tissues, including marrow, synovium, periosteum, muscle, liver, dermis, spleen, thymus, umbilical cord blood/placental blood (UCB), cord matrix, amniotic fluid, placenta, fetal liver, and adipose tissue^{6,7,11,12}. Umbilical cord MSCs (UC-MSCs) for stem cell therapy have advantages over bone marrow MSCs (BM-MSCs) because they are easily available, collection from the donor is not invasive or painful, and there are no ethical considerations¹³. UC-MSCs are more primitive than BM-MSCs and have the capability to differentiate into different cells¹⁴⁻¹⁷.

MSCs derived from a number of both allogeneic and autologous sources have been rapidly gaining momentum. There are number of current clinical trials listed on clinicaltrials.gov and a handful of FDA approvals for their use in various countries outside of the US.

BLUE HORIZON CELLS

Blue Horizon Stem Cell (BHSC) program is associated with the Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China. BHSC has safely and efficiently treated more 600 patients with documenting each procedure. In the study conducted by Jiang et al human bone marrow-derived mesenchymal stem cells transplantation has demonstrated its effectiveness for the treatment of spinal cord injury¹⁸.

The purpose of present study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of UC-MSCs, and secondly, to evaluate effects on biomarkers associated with chronic inflammation. The study was approved by Institutional Review Board of the Institute of Regenerative Cellular Medicine (US Department of Health and Human Services, IRB # 00009500. Protocol #: BH-IN-7101b, IRB Approval Number: IRCM 2014-040).

MATERIALS AND METHODS

Nine patients were treated for conditions associated with chronic inflammation and for the purpose of anti-aging. Chronic inflammatory diseases included osteoarthritis, post traumatic arthritis, inflammatory

back pain, left shoulder bursitis and herniated disc. They have been given one intravenous infusion of UC-MSCs (1.25 ml of 1.0×10^8 stem cells).

I. PROTOCOL

PREPARATION OF UC-MSCs

Umbilical cord bloods were collected from primiparous pregnant women receiving Caesarean section in accordance with the sterile procedure guidelines in each hospital. UC blood samples were processed within 4 hours.

ISOLATION OF MSCs FROM UMBILICAL CORD BLOODS.

Cord blood sample was diluted with phosphate buffer saline (PBS) (1:1). 15 mL of Ficoll-Hypaque pipetted into a 50 mL conical centrifuge tube. 30 mL of the mixture of PBS and sample slowly layered over the Ficoll-Hypaque and centrifugated 30 min at 450 g. Using Pasteur pipette, the interface layer containing the mononuclear cells was transferred to a centrifuge tube. Cells were washed with PBS and recovered by centrifugation for 10 min at 200 g and room temperature. The cell pellet was re-suspend in PBS and the washing procedure was repeated. The cells were counted and 4×10^8 cells were re-suspended in 5 mL cryopreservation solution (10 % DMSO).

STERILITY ASSURANCE

The pregnant donor women passed medical examinations before they donate UC. They tested for communicable diseases such as HBV, HCV, HIV and Syphilis. After collection, each cord blood sample was tested for communicable diseases such as HBV, HCV, HIV and Syphilis. The isolated cells were cultured to test for bacteria and fungus, endotoxins, and to insure viability.

TRANSPORTATION AND CRYOPRESERVATION PROTOCOLS

Cells were analysed by FACS sorter. An automated temperature control device was placed in the transport package with the cells. For the purpose of this pilot study, all cells were hand delivered.

THAWING

Each frozen tube of UC-MSCs was thawed by placing in 37-degree C water bath for one minute with water level not exceeding 80% of the body of the cryotube. The tube was quickly pulsed down and content was transferred to a sterile syringe for the subsequent infusion steps.

The viability of thawed cells was evaluated with the trypan blue exclusion test.

1.25 ml of 1.0×10^8 stem cells stem cells were suspended in 100 ml of saline and usually infused in the patient no more than one hour. Human Albumin (final 1%) was added to the saline for stabilization.

OUTCOME MEASURES: SAFETY EVALUATION AND EFFECTS ON CHRONIC INFLAMMATION

Blood test included general health blood test panel and inflammatory markers (CRP, IL-6, IL-8, TNF-alpha and Fibrinogen). Blood tests were carried out before stem cell treatment and within three months after stem cell treatment. At 0, 3, 6 month intervals the patient have been interviewed and asked to fill out a SF-36 questionnaire. During the interview patients were asked about adverse reactions connected to stem cell treatment, including pain, chills, fever, hives, chest pain, drop in blood pressure, shortness of breath, nausea, flushing, and headache. Additional secondary outcome measures included sleep, energy level, libido, mood, skin, hair and nails growth. All questioners were approved by Institutional Review Board of the Institute of Regenerative Cellular Medicine.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

This article does not contain any studies with animal subjects.

STATISTICAL ANALYSIS

Methods of descriptive statistics (significance is equal to 95%) and probability theory were used.

RESULTS

ISOLATION AND CHARACTERIZATION OF MSCs

MSCs were isolated from umbilical cord bloods from healthy births. Each cord blood sample was tested for communicable diseases such as HBV, HCV, HIV and Syphilis. The isolated cells were cultured to test for bacteria and fungus, endotoxins, and to insure viability (Table 1).

Each frozen tube of umbilical cord derived MSC was thawed and the viability of thawed cells was evaluated with the trypan blue exclusion test.

In average stem cells viability was 83.1 ± 0.57 (Descriptive statistics: Mean = 83.1; Std error = 0.57) (Table 2).

INFUSION AND SAFETY EVALUATION

1.25 ml of 1.0×10^8 stem cells stem cells were suspended in 100 ml of saline and usually infused in the patient no more than one hour.

To determine the overall safety of the use of intravenous infusion of UC-MSCs, subjects were followed up by the clinic within 24 hours, closely monitored for the first two weeks, and then followed up by analysis of specific biomarkers associated with inflammation, as well as a general blood panel for safety and any additional effects/secondary outcome measures.

Table 1. Umbilical Cord Blood-Derived Mesenchymal Stem Cell Quality Assessment Report (Hubei Provincial Stem Cell Bank).

QA Tests	Sample N								
	1	2	3	4	5	6	7	8	9
Morphology	P*	P	P	P	P	P	P	P	P
Immunophenotype analysis by FACS	P	P	P	P	P	P	P	P	P
Viability	90%	92%	93.5%	90%	90%	92%	91%	93%	90%
Bacteriology	N**	N	N	N	N	N	N	N	N
Virology	N	N	N	N	N	N	N	N	N
Mycology	N	N	N	N	N	N	N	N	N
Maternal Blood HIV-1/2 Antibodies	N	N	N	N	N	N	N	N	N
Maternal Blood HCV antibody	N	N	N	N	N	N	N	N	N
Maternal Blood CMV-IgM	N	N	N	N	N	N	N	N	N
Endotoxins	P	P	P	P	P	P	P	P	P

*P – pass

**N – Negative

Table 2. Stem cells viability/cell count.

Sample N	Cell Count	Viability
1	1.2x10 ⁷ MNC*	82%
2	1.42x10 ⁷ MNC	85%
3	1.55x10 ⁷ MNC	82%
4	1.58x10 ⁷ MNC	82%
5	1.86x10 ⁷ MNC	85.2%
6	1.28x10 ⁷ MNC	83%
7	1.68x10 ⁷ MNC	80.7%
8	1.77x10 ⁷ MNC	85.5%
9	1.28x10 ⁷ MNC	82.4%

*Mononuclear Cells (MNC)

BLOOD WORK RESULTS ANALYSIS

Patients' blood work (up to 100 tests) mostly did not reveal the changes connected to stem cells infusion. Blood tests (general blood panel and specific biomarkers associated with inflammation) were carried out before stem cell treatment and within three months after stem cell treatment. It allows with high degree of probability to conclude that introduction of stem cells to patients doesn't influence blood markers. Hence, assuming that the infusion of stem cells with 50% probability can lead to changes of blood markers (50% is the maximum entropy), with 99.2% of probability it is possible to conclude that this treatment doesn't lead to essential changes in blood markers and the stem cell treatment was safe for the patients.

FOLLOW UP PROTOCOLS AND QUESTIONNAIRES

At 0, 3, 6 month intervals the patient were interviewed and asked to fill out questionnaires.

Analysis of different indicators of chronic inflammation and anti-aging included in initial, 24-hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover data from follow up protocols demonstrate significant change in three indicators: energy level, hair and nails growth, skin. Particularly, follow up protocols from 9 patients showed increase in energy level (from

33.3±16.7% at 24 hours to 66.7%±16.7% at 3 months), hair and nails grow (from 11.1%±11.1% at 2 weeks to 44.4%±17.6% at 3 months) and skin improvement (from 11.1%±11.1% at 2 weeks to 44.4%±17.6% at 3 months) (Table 3).

DISCUSSION

Early clinical data indicates that MSCs, either directly or by inducing an anti-inflammatory milieu, can be used for tissue repair in toxic injury or fistulas in Crohn's disease^{19,20}. Clinical results of patients with neurological disorders such as amyotrophic lateral sclerosis or spinal cord injury seem to be encouraging as well^{21,22}. In addition, MSC applications to promote wound healing have demonstrated safety and efficacy in published pilot studies^{23,24}.

Our study of blood test markers (general blood panel and specific biomarkers associated with inflammation) of 9 patients with chronic inflammation demonstrates that there is no significant changes before and after stem cell treatment and the stem cell treatment was safe for the patients.

Many clinical studies and animal experiments have confirmed that the injection of MSCs has favorable effects on wound repairing, immunomodulation, and anti-apoptosis via a paracrine effect or differentiation^{25,26}. Recent studies²⁷ also revealed that adipose-derived stem cells improve wrinkles resulting from photo-aging and promote collagen synthesis and epidermal thickening of photo-aged fibroblasts *in vitro*. Nakagawa et al²⁸ suggest that hMSCs together with bFGF in a skin defect model accelerate cutaneous wound healing as the hMSCs transdifferentiate into the epithelium. Zhang et al²⁹ demonstrated that MSCs may contribute to the regeneration of skin during aging. Several interesting studies³⁰ have been done in the last few years to investigate the role of stem cells in alopecia. Fukuoka et al³¹ demonstrated that hair regenerative therapy was effective for hair growth and is a potential alternative for hair regeneration in patients who are unwilling or unsuitable to undergo traditional surgical hair transplantation.

Table 3. Changes in indicators associated with chronic inflammation and anti-aging.

Parameters	24 hours after treatment	2 weeks after treatment	3 months after treatment
Increased energy level	33.3±16.7%	55.5%±17.6%	66.7%±16.7%
Hair and nails grow faster	–	11.1%±11.1%	44.4%±17.6%
Improved skin	–	11.1%±11.1%	44.4%±17.6%

In our study, follow up protocols from 9 patients with chronic inflammation demonstrate that energy level, hair, nails and skin conditions may improve significantly following stem cell infusion (Figure 1).

CONCLUSIONS

In summary, intravenously administered human cord blood stem cells were safe and effective in the treatment of symptoms related to chronic inflammation. Further close monitoring of 9 patients and inclusion of more patients with chronic inflammation are necessary to fully characterize the advantages of human cord blood stem cells application in treatment of symptoms related to chronic inflammation.

ACKNOWLEDGMENT

The authors are grateful to all the individuals participating in this study. The study would not have been possible without successful cooperation between Department of Stem Cells, Wuhan Hongqiao Brain Hospital, Blue Horizon Stem Cells (Hackensack, NJ, USA) and medical staff and nurses at the International Center for Minimally Invasive Spine Surgery (Wyckoff, NJ, USA).

AUTHORS' DECLARATION OF PERSONAL INTERESTS:

BM sponsored the study and LQ the supervision. MM analyzed the viability of thawed stem cells and was involved in data analyzing and drafting the manuscript. PW have been involved in drafting the manuscript. DW provided MSCs from China and was the consulter of research study.

DECLARATION OF FUNDING INTERESTS:

This study was sponsored by Blue Horizon International. Fees for the study were subsidized by Blue Horizon Charitable Foundation. Brian Mehling is the president and Chief Medical Officer at the Blue Horizon International.

REFERENCES

1. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. *Recent Pat Inflamm Allergy Drug Discov* 2009; 3(1): 73-80.
2. Calder PC, Albers R, Antoine JM, Blum S Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, Løvik M, Macfarlane S, Meyer PD, M'Rabet L, Serafini M, van Eden W, van Loo J, Vas Dias W, Vidry S, Winkhofer-Roob BM, Zhao J. et al. Inflammatory disease processes and interactions with nutrition. *Br J Nutr* 2009; 101 Suppl 1: S1-45.
3. Lukens JR, Gross JM, Kanneganti TD. IL-1 family cytokines trigger sterile inflammatory disease. *Front Immunol* 2012; 3: 315
4. Voswinkel J, Francois S, Simon JM, Benderitter M, Gorin NC, Mohty M, Fouillard L, Chapel A. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. *Clin Rev Allergy Immunol* 2013; 45(2): 180-192.
5. Perdikogianni C, Dimitriou H, Stiakaki E, Martimianaki G, Kalmanti M. Could cord blood be a source of mesenchymal stromal cells for clinical use? *Cytotherapy* 2008; 10(5): 452-459.
6. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. *Br J Haematol* 2000; 109(1): 235-242.
7. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells* 2004; 22(7): 1338-1345.
8. Panepucci RA, Siufi JL, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT, Zago MA. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. *Stem Cells* 2004; 22(7): 1263-1278.
9. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; 418(6893): 41-49.
10. Mareschi K, Ferrero I, Rustichelli D, Aschero S, Gammaitoni L, Aglietta M, Madon E, Fagioli F. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. *J Cell Biochem* 2006; 97(4): 744-754.




Figure 1. Improvement in energy level, hair, nails growth and skin condition following stem cell treatment.

11. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bonemarrow. *Blood* 2001; 98(8): 2396-2402.
12. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells* 2004; 22(7): 1330-1337.
13. Wu LF, Wang NN, Liu YS, Wei X. Differentiation of Wharton's jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. *Tissue Eng Part A* 2009; 15(10): 2865-2873.
14. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. *Stem Cells* 2005; 23(2): 220-229.
15. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis- supportive function and other potentials. *Haematologica* 2006; 91(8): 1017-1026.
16. Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. *Stem Cells* 2007; 25(11): 2886-2895.
17. Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du WT, Gu DS, Han ZC, Liu YL. In vitro and *in vivo* differentiation of human umbilical cord derived stem cells into endothelial cells. *J Cell Biochem* 2007; 100(3): 608-616.
18. Jiang PC, Xiong WP, Wang G, Ma C, Yao WQ, Kendell SF, Mehling BM, Yuan XH, Wu DC. A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury. *Exp Ther Med* 2013; 6(1): 140-146.
19. Ringdén O, Uzunel M, Sundberg B, Lönnies L, Nava S, Gustafsson J, Henningssohn L, Le Blanc K. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. *Leukemia* 2007; 21(11): 2271-2276.
20. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis Colon Rectum* 2005; 48(7): 1416-1423.
21. Kang KS, Kim SW, Oh YH, Yu JW, Kim KY, Park HK, Song CH, Han H. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. *Cytherapy* 2005; 7(4): 368-373.
22. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Boccaletti R, Testa L, Livigni S, Fagioli F. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. *Neurol Res* 2006; 28(5): 523-526.
23. Bystrov AV, Polyaev YA, Pogodina MA, Rasulov MF, Krashennnikov ME, Onishchenko NA. Use of autologous bone marrow mesenchymal stem cells for healing of free full-thickness skin graft in a zone with pronounced hypoperfusion of soft tissues caused by arteriovenous shunting. *Bull Exp Biol Med* 2006; 142(1): 123-128.
24. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shraye D, Carson P. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. *Tissue Eng* 2007; 13(6): 1299-1312.
25. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. *J Cell Physiol* 2007; 212(3): 702-709.
26. Meliga E, Strem BM, Duckers HJ, Serruys PW. Adipose-derived cells. *Cell Transplant* 2007; 16(9): 963-970.
27. Kim WS, Park BS, Park SH, Kim HK, Sung JH. Antiwrinkle effect of adipose-derived stem cell: activation of dermal fibroblast by secretory factors. *J Dermatol Sci* 2009; 53(2): 96-102.
28. Nakagawa H, Akita S, Fukui M, Fujii T, Akino K. Human mesenchymal stem cells successfully improve skin-substitute wound healing. *Br J Dermatol* 2005; 153(1): 29-36.
29. Zhang S, Dong Z, Peng Z, Lu F. Anti-aging effect of adipose-derived stem cells in a mouse model of skin aging induced by D-galactose. *PLoS One* 2014; 9(5): e97573.
30. Al-Refu K. Stem cells and alopecia: a review of pathogenesis. *Br J Dermatol* 2012; 167(3): 479-484.
31. Fukuoka H, Suga H, Narita K, Watanabe R, Shintani S. The Latest Advance in Hair Regeneration Therapy Using Proteins Secreted by Adipose-Derived Stem Cells. *Am J Cosmet Surg* 2012; 29: 4.